Biologic Drugs With Mechanism of Action: HER1 Antagonists
✉ Email this page to a colleague
Biologic Drugs With Mechanism of Action: HER1 Antagonists
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 2004-02-12 | ⤷ Start Trial | ⤷ Start Trial |
| Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 2004-02-12 | 6,217,866 | ⤷ Start Trial |
| Amgen, Inc. | VECTIBIX | panitumumab | Injection | 125147 | 2006-09-27 | ⤷ Start Trial | ⤷ Start Trial |
| Amgen, Inc. | VECTIBIX | panitumumab | Injection | 125147 | 2006-09-27 | 6,235,883 | ⤷ Start Trial |
| Amgen, Inc. | VECTIBIX | panitumumab | Injection | 125147 | 2006-09-27 | 7,807,798 | ⤷ Start Trial |
| Eli Lilly And Company | PORTRAZZA | necitumumab | Injection | 125547 | 2015-11-24 | ⤷ Start Trial | ⤷ Start Trial |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Patent Expiration |
